Due to the limited sample size, we do not have enough information to determine the association between hospital outcomes and the use of sodium-glucose cotransporter-2 inhibitors, which has been suggested to increase the likelihood of COVID-19-related ketoacidosis among patients with severe insulin deficiency [32]. Here, SLC5A2 is linked to COVID-19.